CoreCivic Sold the Beds, Retired the Debt and a Seventh of Itself — Now It Has to Live on the Per Diem

$2.2 billion of real estate handed to the federal government at replacement cost, a share count cut 13.8%, and a 2027 run-rate math that argues the easy money is done

CXW · Earnings Call · 2026-11-05

A balance-sheet quarter dressed as an operating one

CoreCivic's third quarter was not an operating quarter so much as a balance-sheet event wearing an operating quarter's clothes. The company sold four detention facilities — 7,190 beds — to the Department of Homeland Security for $2.2 billion gross, netting roughly $1.6 billion after transaction costs and some $500 million of federal and state tax. The average price was $307,000 per bed, a range running from $371,000 at Otay Mesa in California down to $231,000 at the Midwest facility in Kansas. Management was emphatic this was not a negotiated number but an appraisal: value set under government-mandated fair market value standards directing appraisers to replacement cost. “Under this federal statutory framework, the sales price rests on the appraiser's independent conclusions and the government's review of them. Not a price set by either party.” — Lucibeth N. Mayberry, President and Chief Executive Officer · 2026-11-05 That framing is the entire bull case in one sentence. The market had been valuing a bed as a per-diem stream; the federal government just valued it as a replacement-cost asset. Proceeds were then converted into a different company within ninety days. Over $700 million of debt was repaid inside the quarter — the revolver, both term loans, the 2027 notes — for an expected $40 million of annual interest savings. A $500 million accelerated share repurchase took immediate delivery of 12.4 million shares, cutting weighted diluted shares 13.8% year over year, and the board added another $500 million of authorization days later. The result: “As of September 30, excluding a non recourse mortgage, we now have more cash than debt with $1.1 billion of total liquidity available consisting of $547 million of cash on hand and $551 million of undrawn borrowing capacity under our revolving credit facility.” — David Garfinkle, Chief Financial Officer · 2026-11-05 From a net debt position of roughly $1.2 billion at the June quarter to net cash is the single most important fact in this report — and it is visible only in the 10-Q, not the earnings release. Operations were genuinely good in their own right. Residential occupancy hit 84%, the highest since the pandemic and up 7.3 points, with average daily population up from 55,200 to 60,300. Adjusted EBITDA of $117.8 million rose 33%; adjusted EPS of $0.49 more than doubled; normalized FFO per share rose 56%.

The part the headline buries

Here is where the quarter gets more interesting. The operating beat is partly borrowed from the future. Management explicitly said Q3 margins benefited from contract modifications at the four sold facilities that have not happened yet, and in August the CFO refused to size that: “we are not specifically quantifying them for obvious reasons. Those negotiations are not yet complete.” — David Garfinkle, Chief Financial Officer · 2026-08-06 A quarter whose beat leans on the very adjustment they would not quantify is a beat you discount. The 2027 bridge is the arithmetic the tape is trading. “If you extrapolated that for a full year, you would end up around $426 million in guidance in a run rate EBITDA” — David Garfinkle, Chief Financial Officer · 2026-11-05 — the CFO annualizing a clean Q4, adding perhaps $10 million for the newly awarded Appleton facility, and landing at $436–450 million for 2027 versus $442.5–445.5 million for 2026. Guidance went up for this year; the run-rate math goes sideways or slightly down next year. On the per-diem question itself — the second-ranked company keyword this quarter was diem increased, tied to traditional inflation-related escalators — analyst Joe Gomes asked directly whether state or federal partners had pushed back on increases. The answer was a flat no, followed by the mechanism: “I think on the federal side, most of our per diem increases are built into the contracts. So they are just kind of a matter of course.” — David Garfinkle, Chief Financial Officer · 2026-11-05 So a keyword flagged as a live theme is, on management's account, a non-event — either reassuring (escalators working mechanically) or a sign that state increases are quietly embedded in guidance rather than discussed.

What ICE does next — and what management can't promise

Detention capacity sits at the top of the company keyword table for the second time in two years, which is the point: it is not a new story, it is the story. Four idle corrections facilities holding 5,500 beds remain ready, and discussions about selling additional assets are live but, in the company's own word, preliminary. The CEO did not hide her impatience:

While discussions are preliminary and we cannot predict what will happen... we would urge... ICE administration to move quickly. I think they have a need for capacity. We have the capacity. There is no reason to wait.
Lucibeth N. Mayberry, President and Chief Executive Officer · 2026-11-05

The qualitative backdrop shifted too. In August the narrative was that DHS had de-emphasized the warehouse strategy; this quarter management said plainly that ICE “seem to have a few of the warehouse solutions that they are focused on. We have seen them pull back from a broader usage of any of the, you know, less traditional, capacity.” — Lucibeth N. Mayberry, President and Chief Executive Officer · 2026-11-05 That retreat is precisely what makes the Federal Government concentration more valuable — and more dangerous. Federal partners are 53% of revenue; ICE revenue rose $75.2 million, or 34.8%, while the U.S. Marshals Service actually fell $5.2 million. Single-customer, single-policy dependence is the whole business, and the funding underpinning it runs to 2029. Both keyword sets caught the political frame around this: market-wide, election outcome and new Congress rank high this quarter, and analysts asked repeatedly whether the midterms change ICE's appetite or timing. Management's answer was that nationwide populations are stable around 69,000 and that they are as ready as they were before the vote.

The tape disagrees, loudly

CoreCivic shares are down about 9% over the last ninety trading days and roughly 21% from the September 17 peak of $35.54. Zoom out and the full-history tape is a savaging followed by a doubling: a 19-week run of +146%, then a long round-trip, with the all-time high still the 2015 mark of $42.10. This is a stock that already re-rated hard on the ICE capacity thesis and is now consolidating while the company executes the largest value-realization event in its history. The valuation argument has not aged well in the telling. The then-CEO framed it precisely in August: “our multiple today... is approximately 6x EBITDA, which is well below our historical EBITDA multiple average over the last 20 years of 9.5 times” — Patrick Swindle, President and Chief Executive Officer · 2026-08-06 — implying $48 a share at the historical average. Today the language is softer and the messenger new: “we continue to believe that our current share price implies a significant discount to the fair value” — Lucibeth N. Mayberry, President and Chief Executive Officer · 2026-11-05, that enterprise-value-to-EBITDA remains contracted, and that buybacks are an attractive use of capital. The price-to-revenue ratio of 1.2x is up from 2024 lows but far below 2016 highs, and the 6.9% operating margin, down 2.8 points year over year, shows higher occupancy is not yet converting into the 25%-plus margins management once flagged as achievable at 80% utilization. With interest coverage of 2.1x, down from 4.2x a year ago, the deleveraging is real but the income statement has not yet felt it. The other structural thread is where the next dollar goes. Strategic acquisitions is a fresh top-ten company keyword, and Clinical Solutions Pharmacy is the template: $148 million initial price, blended under 6x with Farmville, $82.8 million of revenue in the quarter, lifting services to 6.1% of segment net operating income from 0.9%. A management team that just learned its real estate trades at replacement cost would be forgiven for wondering whether a pharmacy platform does. What we have is a company whose balance sheet transformed in ninety days, whose guidance rose, whose 2027 run-rate math suggests a plateau, whose CEO changed hands for health reasons in September, and whose stock is voting that the transformation was already in the price. The striking thing is not that the numbers were good. It is that a $1.3 billion gain and a seventh of the share count retired bought roughly nine points of underperformance. Executing the trade is now the easy part; the question is whether ICE — not the appraiser — sets the next per diem.